Last reviewed · How we verify

NALIRIFOX plus targeted therapy

Shanghai Zhongshan Hospital · Phase 3 active Small molecule

NALIRIFOX is a combination of nal-IRI (irinotecan liposomal) and 5-fluorouracil that inhibits topoisomerase I and nucleotide synthesis, combined with targeted therapy to enhance anti-tumor activity.

NALIRIFOX is a combination of nal-IRI (irinotecan liposomal) and 5-fluorouracil that inhibits topoisomerase I and nucleotide synthesis, combined with targeted therapy to enhance anti-tumor activity. Used for Metastatic pancreatic cancer or other solid tumors (specific indication under investigation in phase 3).

At a glance

Generic nameNALIRIFOX plus targeted therapy
SponsorShanghai Zhongshan Hospital
Drug classCombination chemotherapy with targeted therapy
TargetTopoisomerase I, thymidylate synthase, and variable molecular targets depending on targeted therapy partner
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Nal-IRI is a liposomal formulation of irinotecan that stabilizes topoisomerase I-DNA complexes, leading to DNA damage and cell death. When combined with 5-FU (which inhibits thymidylate synthase and incorporates into DNA/RNA) and targeted therapy agents, this combination aims to improve efficacy in difficult-to-treat cancers. The targeted therapy component is designed to address specific molecular drivers in the tumor.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: